Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis
This study has been completed.
Study NCT00004829   Information provided by FDA Office of Orphan Products Development
First Received: February 24, 2000   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
Bacterial Infection
Additional conditions recognized in this trial
Bacterial Infections
Communicable Diseases
Fibrosis
Infection
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
tobramycin
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services